All In Biotech

Drug Trial Radar · NCT07053215

Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC

Efficacy of Argon-Helium Cryoablation Combined With PD-1 Inhibitors in Non-Small Cell Lung Cancer: A Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Dec 1, 2020

Primary completion

Dec 1, 2024

Study completion Dec 1, 2024

Sponsor

Lead sponsor
The First Hospital of Hebei Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized controlled trial investigated the efficacy and safety of argon-helium cryoablation combined with PD-1 inhibitors compared to PD-1 inhibitors plus chemotherapy for treating non-small cell lung cancer (NSCLC). The study aimed to evaluate differences in survival, tumor response, immune function, and adverse events.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • Argon-Helium CryoablationDevice

    Procedure performed within 7 days before the first dose of PD-1 inhibitor. CT-guided insertion of cryoprobes into the target tumor. Two freeze-thaw cycles: rapid freeze to -135°C to -145°C for 15-20 minutes, followed by thawing.

  • CamrelizumabDrug

    200 mg intravenously every 3 weeks for 4 cycles.

  • Platinum-based doublet chemotherapyDrug

    * Non-squamous NSCLC: Pemetrexed (500 mg/m² IV on day 1) plus Carboplatin (AUC 5 mg/mL•min IV on day 1) of each 3-week cycle. * Squamous NSCLC: Gemcitabine (1250 mg/m² IV on days 1 and 8) plus Carboplatin (AUC 5 mg/mL•min IV on day 1) of each 3-week cycle. * Administered for 4 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From randomization until death, assessed through study completion, an average of 1 year.
  2. Progression-Free Survival (PFS)Time frame: From randomization until disease progression or death, assessed through study completion, an average of 1 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • the First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.